BPI and Crohn disease: Among the studies carried out, a reduction in mortality in children with meningococcal sepsis (clinical phases II and III) [11,42] and beneficial effects in patients with Crohn’s disease (clinical phase II) [43] stand out in both cases when treated with an N-terminal fragment of recombinant BPI (rBPI21).